Safety, tolerability, pharmacokinetics and effect on serum uric acid of the myeloperoxidase inhibitor AZD4831 in a randomized, placebo‐controlled, phase I study in healthy volunteers

AIMS: Myeloperoxidase activity can contribute to impaired vascular endothelial function and fibrosis in chronic inflammation‐related cardiovascular disease. Here, we investigated the safety, tolerability and pharmacokinetics of the myeloperoxidase inhibitor, AZD4831. METHODS: In this randomized, sin...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:Br J Clin Pharmacol
Autores principales: Gan, Li‐Ming, Lagerström‐Fermér, Maria, Ericsson, Hans, Nelander, Karin, Lindstedt, Eva‐Lotte, Michaëlsson, Erik, Kjaer, Magnus, Heijer, Maria, Whatling, Carl, Fuhr, Rainard
Formato: Artigo
Lenguaje:Inglês
Publicado: John Wiley and Sons Inc. 2019
Materias:
Original Articles
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC6422671/
https://ncbi.nlm.nih.gov/pubmed/30618054
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/bcp.13855
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares